Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2015

View Archived Issues

Chugai reviews domestic and international developments of fourth quarter 2014

Eisai profiles developments of third quarter of fiscal 2014

Pfizer profiles pipeline progress of fourth quarter 2014

Novel BRD4 inhibitors disclosed by Bayer Schering Pharma

Merck & Co. divulges novel IRAK-4 inhibitors

Astex patents novel inhibitors of discoidin domain receptors

Glenmark Pharmaceuticals discloses new RORgamma-t modulators

Novartis reports new E-NPP 2 inhibitors

Acorda reports data from phase I trial of remyelinating antibody in MS

FDA grants breakthrough therapy designation to LentiGlobin for beta-thalassemia major

DiaMedica to develop DM-199 for acute vascular diseases

Lpath submits IND application for Lpathomab in neuropathic pain

Amitiza mutual recognition procedure closes with recommendation for approval

Researchers identify potential biomarker of keloid tissue formation

Symphogen regains rights to Sym-004 and focuses on oncology

IncellDx's OncoBreast3Dx technology set for studies in detection of early-stage breast cancer

Endo completes acquisition of Auxilium Pharmaceuticals

BioMarin completes tender offer for Prosensa stock

Alnylam begins phase I/II trial of ALN-CC5 for complement-mediated diseases

Cis-urocanic acid eye drops found safe in phase I study

Phase II/III study of two Ebola vaccines initiated in Liberia

Parent Project Muscular Dystrophy awards grant to UCLA team to develop exon skipping boosters

Repros submits Androxal NDA

FDA approves Glyxambi for type 2 diabetes

Afrezza launched in U.S.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...